BioTech

Biotech Stocks Shake Off Fears of Greek Crisis

About Raynovich Rod
Rod Raynovich is an experienced biotech investor and analyst with a focus in vaccines, tools, IVD’s and biopharmaceuticals. Prior to starting Raygent.com, he was a former technology transfer office at UCLA and he has held various executive positions in the biotech and medical device industry, including senior positions at NASDAQ listed biomedical companies. Prior to that Mr.Raynovich held […]

Forget Biogen (BIIB), Buy These 3 Biotechnology Stocks Instead …

One of the most popular and well-known names in the biotech world is definitely Biogen (BIIB-Analyst Report). This large cap stock has been a staple of investor portfolios in the biotechnology space for some time, while it is also one of the behemoths of the sector, closing in on $100 billion in market cap.BIIB might be due for a breather […]

#MarketUpdate: It’s all Greek to me…The markets opened in the…

#MarketUpdate: It’s all Greek to me…The markets opened in the red as expected, rallied to near unchanged and at midday are just modestly lower. The Dow is off 44 points, Nasdaq Comp in the red by 14 pts, S&P-500 lower by 6pts, and the Russell 2000 is holding up the best with only a 3 point loss. For some context, […]

TPP to reshape stock portfolios with trade flows

WASHINGTON: Buy Japan. Buy Vietnam. Buy US media stocks. Buy Mexican food stocks. Sell China.For investors wanting to take advantage of the Pacific Rim free trade pact that appears to be nearing completion, that’s what a savvy stock strategy might look like.The 12 nations of the Trans-Pacific Partnership (TPP) could wrap up an agreement in coming weeks, after the pact […]

Happy Holiday – 2015 at the Halfway Point

The first half of 2015 has come and gone, and the long-running global bull market has significantly faltered.The Dow Jones Industrial Average fell 1.4% through the first six months of 2015, the first time the index has lost ground in that time frame since 2010. The S&P 500 eked out a 0.2% gain in the first half, its smallest H1 […]

Several Biotech Stocks Indicating A Macro Short Strategy | Seeking …

SummaryOvaScience, Sarpeta Therapeutics, Ziopharm Oncology and Keryx Biopharmaceuticals all have a short interest above 20%.
These small cap biotech companies provide attractive characteristics for fundamental weakness through liquidity needs, no revenue and a higher fail rate.
Given these common variables, there is strong indication that a large Marco short strategy has been put in place.
This large short position provides opportunities for contrarian […]

How to Survive a Screwball Market

If you don’t want to lose your shirt this month, you have to buy the strongest trends on the market. Period.So today is your final installment of this week’s post-Greece craziness “search for strength” coverage.I showed you yesterday how health care and biotech stocks are the strongest and safest     names on the market right now. And today I’m showing you […]

My Marketocracy Fund was up 23% in first half of 2015

2015 to date, has been good for my model fund. I am up 23% vs 0% for the S&P500 and vs 20% for the IBB biotech index.
My long-term performance also remains strong – I have turned 385% over the past 10 years vs 76% for the S&P500.I anticipate the second half of 2015 will also be good for my fund. […]

Advaxis, Inc. (ADXS) Down 10% Today: What Do Hedge Funds Think about this …

Advaxis, Inc. (NASDAQ:ADXS) is a biotechnology company which focuses on developing drug technology for treating Cancer. Alongside many other biotech stocks, Advaxis, Inc. (NASDAQ:ADXS)’s shares surged by 108% so far in 2015. However, in the last 30 days, the stock is down by 25%. Today, Advaxis is down by around 10%, after jumping by 17% on Tuesday. There have been […]

A Sector Immune to Greece

“By declaring Greece in arrears, the IMF avoided using the term ‘default,’” says this morning’s New York Times.If you read yesterday’s 5 Minute Forecast, you already knew that’s what would happen. The Greek government missed a $1.7 billion payment to the International Monetary Fund. But don’t call it a default.The U.S. finance industry played this game a few years ago. […]